Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Nestle Cuts Sales Forecast as Shoppers Reject Price Hikes
- Social Security Payments Worth Over $4,800 To Go Out This Week; Here’s When You’ll Get Yours
- US Could See Another ‘Great Resignation’ as 3 in 10 Workers Plan To Quit in 2024: Survey
- Uber, Lyft Drivers Remain as Contractors After California Supreme Court Upheld Proposition 22
- Walmart Eyes $200 Million Investment in Autonomous Forklifts
- Maersk Agrees to Settlement with US Labor Department After Firing Whistleblower
- Delta’s CEO Flew to Paris for the Olympics While His Company Is Under Federal Investigation: Report
- Wiers Farm Recalls Produce Products Due To Potential Listerian Contamination